UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

In Re: TAXOTERE (DOCETAXEL)

MDL NO. 2740

PRODUCTS LIABILITY

LITIGATION

SECTION "N" (5)

THIS DOCUMENT RELATES TO:

ALL CASES

PRETRIAL ORDER NO. 18

[Plaintiff Fact Sheet and Defendant Fact Sheet]

Pursuant to this Court's Orders of December 21, 2016 (R. Doc. 140) and January 11, 2017

(R. Doc. 170), on January 20, 2017, the parties submitted counterproposals on the form of the

Plaintiff and Defendant Fact Sheets. After reviewing the respective submissions of the parties,

IT IS ORDERED that the document attached to this Order as Exhibit A will be the

operable Plaintiff Fact Sheet in this matter;

IT IS FURTHER ORDERED that the document attached to this Order as Exhibit B will

be the operable Defendant Fact Sheet in this matter; and

IT IS FINALLY ORDERED that the parties will be required to complete and submit for

the Court's consideration the authorizations to be attached to Exhibit A, and the deadlines and

guideline/rules for implementation of these forms in a Proposed Order through Liaison Counsel

no later than Friday, March 3, 2017.

New Orleans, Louisiana, this 14th day of February, 2017.

KURT D. ENGELHARD)

UNITED STATES DISTRACT JUDGE

1

UNITED STATES DISTRICT COURT

EASTERN DISTRICT OF LOUISIANA

In Re: TAXOTERE (DOCETAXEL) MDL NO. 2740

PRODUCTS LIABILITY

LITIGATION

SECTION "N" (5)

THIS DOCUMENT RELATES TO ALL CASES

PLAINTIFF FACT SHEET

This Fact Sheet must be completed by each plaintiff who has filed a lawsuit related to the use of Taxotere® by the plaintiff or a plaintiff's decedent. Please answer every question to the best of your knowledge. In completing this Fact Sheet, you are under oath and must provide information that is true and correct to the best of your knowledge. If you cannot recall all of the details requested, please provide as much information as you can. You must supplement your responses if you learn that they are incomplete or incorrect in any material respect.

In filling out this form, please use the following definitions: (1) "healthcare provider" means any hospital, clinic, medical center, physician's office, infirmary, medical or diagnostic laboratory, or other facility that provides medical, dietary, psychiatric, or psychological care or advice, and any pharmacy, weight loss center, x-ray department, laboratory, physical therapist or physical therapy department, rehabilitation specialist, physician, psychiatrist, osteopath, homeopath, chiropractor, psychologist, nutritionist, dietician, or other persons or entities involved in the evaluation, diagnosis, care, and/or treatment of the plaintiff or plaintiff's decedent; (2) "document" means any writing or record of every type that is in your possession, including but not limited to written documents, documents in electronic format, cassettes, videotapes, photographs, charts, computer discs or tapes, and x-rays, drawings, graphs, phonerecords, non-identical copies, and other data compilations from which information can be obtained and translated, if necessary, by the respondent through electronic devices into reasonably usable form.

Information provided by plaintiff will only be used for purposes related to this litigation and may be disclosed only as permitted by the protective order in this litigation. This Fact Sheet is completed pursuant to the Federal Rules of Civil Procedure governing discovery (or, for state court case, the governing rules of civil of the state in which the case is pending).

I. CASE INFORMATION

Attorney Information

Please provide the following information for the civil action that you filed:

	1. Caption:
	2. Court and Docket No.:
	3. MDL Docket No. (if different):
	4. Date Lawsuit Filed:
	5. Plaintiff's Attorney:
	6. Plaintiff's Law Firm:
	7. Attorney's Address:
	8. Attorney's Phone Number:
	9. Attorney's Email Address:
Plaintiff Inform	nation
	Please provide the following information for the individual on whose behalf this action was filed:
	10. Name:
	11. Street Address:
	12. City:
	13. State:
	14. Zip code:
	15. Date of Birth:
	16. Place of Birth:
	17. Social Security Number:
	18. Maiden or other names you have used or by which you have been known:
	19. Sex: Male: □ Female: □
	20. Race:
	Race
	American Indian or Alaska Native

	Race	
	Asian	
	Black or African American	
	Native Hawaiian or Other Pacific Islander	
	White	
21	. Ethnicity:	
	Ethnicity	
	Hispanic or Latino	
	Not Hispanic or Latino	
22	. Primary Language:	
Representative In	formation	
	you are completing this questionnaire in a repr half of the estate of a deceased person), please	
23	. Name:	
24	. Address:	
25	. Capacity in which you are representing the ir	ndividual:
26	. If you were appointed as a representative by and Case Number:	a court, identify the State, Court
	a) State:	
	b) Court:	
	c) Case Number:	
27	. Relationship to the Represented Person:	
28	. State the date of death of the decedent:	
29	. State the place of death of the decedent:	
30	. Are you filling this questionnaire out on beha	alf of an individual who is

deceased and on whom an autopsy was performed? Yes ☐ No☐

If you are completing this questionnaire in a representative capacity, please respond to these questions with respect to the person whose medical treatment involved Taxotere® or Docetaxel.

II. PERSONAL INFORMATION

Relationship I	nfor	mation					
	1.	Are you currently: Married: \square Single: \square Engaged: \square Significant other: \square Divorced: \square Widowed: \square Same sex partner: \square					
	2.	Have you ever been married? Yes □ No□					
	3.	If yes, for EACH marriage, state the following:					
		Spouse's Name	Date of Marriage	Date Marriage Ended	Nature of Termination		
Education							
	4.	For each level of education you completed, please check below:					
	Hig	gh School: \square Vocational School: \square					
	Co	College: AA: \square BA/BS: \square Masters: \square PhD: \square M.D.: \square Other:					
Employment	5.	Are you currently employed? Yes \square No \square					
	6.	If yes, state the following:					
		a) Current employer name:					
		b) Address:					
		c) Telephone number	er:				
		d) Your position the	re:				
	7.	Are you making a claim t	for lost wage	es or lost earr	ning capacity? Yes □ No□		
	8.	Only if you are assertin EACH employer for the l			ease state the following for		

	Name of Employer		ress of oloyer	Dates of Employment	Annual Gross Income	Your Position
	Have you ever related to your h				-	s for reasons
	If yes, please sta			`		
	Name of Em		Date	es Health	Reason	
		Transfer of the second				
IDENTIFY	GT ATTACH TA THE LOSS G LOST WAGE	OF CO	NSORT	IUM PLAINTI	FF'S EMPI	OYERS IF
Worker's Compen	sation and Disab	ility Claim	S			
11. Within the last ten (10) years, have you ever filed for workers' compensation, social security, and/or state or federal disability benefits? Yes □ No□						
12. If yes, then as to EACH application, please state the following:						
	Year Claim Filed	Court	Natu	re of Claimed Injury	Period of Disability	Award Amount
Military Service	L				l	
Willitary Service						
13.	Have you ever se	erved in an	y branch	of the military?	Yes □ No□	
14.	If yes, state the b	oranch and	dates of	service:		
	Branch	1	Dates	of Service		

	15.	15. If yes, were you discharged for any reason relating to your health (whether physical, psychiatric, or other health condition)? Yes □ No□					
	16.	If yes, state the cond	ition:				
Other Lawsuit	ts						
	17.	Within the last ten (10 injury, or made a claim					
Computer Use	e						
	18.	Apart from communicated via er communicated via er comment, message of experience with or in or alopecia/hair loss postings on public so MySpace, LinkedIn,	mail, visited any chat or blog entry on a pub njuries you attribute to during the past ten (1 ocial network sites in	rooms, or public internet site of Taxotere [®] , of 10) years? You cluding Twitter	licly posted a e regarding your ther chemotherapies, should include all r, Facebook,		
	19. If yes, please state the following:						
		Forum Name	Screen Name or User Handle	Date of Post	Substance of Post		
	20.	Are you now or have Yes □ No□	e you ever been a me	mber of an alop	pecia support group?		
	20.	Yes □ No□		_	pecia support group?		
	20.	Yes □ No□ a) If yes, identif	y the group by name	:			
III.PRODUC		Yes □ No□ a) If yes, identif	y the group by name	:			
	CT II	Yes □ No□ a) If yes, identif b) When did you DENTIFICATION ECORDS DEMONS	Ty the group by name u join the group?	:F TAXOTERF			
I HAV	CT II E RI	Yes □ No□ a) If yes, identif b) When did you DENTIFICATION ECORDS DEMONS	Fy the group by name u join the group? STRATING USE OF ETAXEL: Yes □ N	: F TAXOTERE	E [®] OR OTHER		
I HAV	CT II E RI MUS	Yes □ No□ a) If yes, identif b) When did you DENTIFICATION ECORDS DEMONS DOC!	Ty the group by name u join the group? STRATING USE OF ETAXEL: Yes □ NOW SU	: F TAXOTERE TO□ JBMIT THIS	E® OR OTHER FACT SHEET		

Other Docetaxel		
2.	Were you treated with another Docetaxel or generic Taxotere®? Yes [] No□
3.	If yes, select all that apply:	
	Name of Drug	
	Docetaxel – Sanofi-Aventis U.S. LLC d/b/a Winthrop US	
	Docetaxel – McKesson Corporation d/b/a McKesson Packaging	
	Docetaxel – Actavis LLC f/k/a Actavis Inc. / Actavis Pharma, Inc.	
	Docetaxel – Pfizer Inc.	
	Docetaxel – Sandoz Inc.	
	Docetaxel – Accord Healthcare, Inc.	
	Docetaxel – Hospira Worldwide, LLC f/k/a Hospira Worldwide, Inc. / Hospira, Inc.	
	Docefrez – Sun Pharma Global FZE	
	Docefrez – Sun Pharmaceutical Industries, Inc. f/k/a Caraco Pharmaceutical Laboratories, Ltd.	
	Docetaxel – Teva Parenteral Medicines, Inc.	
	Docetaxel – Dr. Reddy's Laboratories Limited	
	Docetaxel – Eagle Pharmaceuticals, Inc.	
	Docetaxel – Northstar Rx LLC	
	Docetaxel – Sagent Pharmaceuticals, Inc.	
	Unknown	
4.	IF YOU SELECTED "UNKNOWN" YOU MUST CERTIFOLLOWS: I certify that I have made reasonable, good faith efforts to identify manufacturer of the Docetaxel used in my treatment, including requesting records from my infusion pharmacy, and the manufact either remains unknown at this time or I am awaiting the records:	the
IV. MEDICAL I	NFORMATION	
Vital Statistics		
1.	How old are you:	
2.	Age at the time of your alleged injury:	
3.	Current weight:	

4. Current height:

	Feet:	Inches:					
5.	Weight at time of alleged in	injury:					
Gynecologic and	Obstetric History						
6.	Have you ever been pregn	ant? Yes □ No □]				
	a) Number of pregnar	a) Number of pregnancies:					
	b) Number of live bir	ths:					
7.	If you have children, pleas	se state the followi	ng for EACH chil	ld:			
	Child's Name	Address	Date of Birt	h			
8.	Date of first period (menses): Age:						
9.	Date of last period (menses): Age:						
10	Are you menopausal, perimenopausal or postmenopausal? Yes □ No□						
11	For EACH year for the last seven (7) years before your first treatment with Taxotere® or Docetaxel and since then, who did you see for your annual gynecological exam? Also indicate whether an annual exam was skipped or missed.						
	Doctor	Office	Year	Skipped or Missed			

Doctor Office Year Skipped or Missed

12. For EACH year after age 40, or before then if applicable, who did you see for

your annual mammogram? Also indicate whether an annual mammogram was skipped or missed.

	Doctor	Office	Year	Skipped or Missed
Other Risk Facto	. Have any family members	been diagnosed	with breast cancer?	
	Family Member	Diagnosed	Age at Diagnosis	3
	Mother			
	Sister			
	Daughter			
	Paternal grandmother			
	Maternal grandmother			
	an increased cancer risk (e. a) If yes, which? 7. Did you receive radiation to 30? Yes □ No□ a) If yes, describe the	reatments or ex	posure to radiation l	pefore the age
Γobacco Use His	tory			
he answer and f	year period before your use of the state of			
16	. I currently use tobacco: Ye	es □ No□		
17	. I have never used tobacco:	V N		
-,	. I have hever used tobacco.	Yes □ No□		

Yes □ No□

19. Identify types of tobacco use:

Туре	Used	Average Per Day	Duration of Use (Years)
Cigarettes			
Cigars			
Pipes			
Chewing tobacco/snuff			

Prescription Medication	Prescri	ption	Medi	cations
-------------------------	---------	-------	------	---------

20. Apart from chemotherapy, are there prescription or over-the-counter
medications that you took on a regular basis or more than three (3) times in
the seven (7) year period before you first took Taxotere [®] ? Yes \square No \square

For purposes of this question, "regular basis" means that you were directed by a healthcare provider to take a medication for at least forty-five (45) consecutive days.

21. If yes, please provide the following for EACH prescription medication:

Medication	Prescriber	Dates Taken

V. CANCER DIAGNOSIS AND TREATMENT

Cancer Diagnosis & Treatment Generally

- 1. Have you ever been diagnosed with cancer? Yes \square No \square
- 2. Were you diagnosed with cancer more than once? Yes \square No \square
- 3. Did you undergo any of the following for cancer?

Treatment	Treated
Surgery	
Radiation	
Chemotherapy	

4. For surgery, specify:

Type of Surgery	Treated
Double mastectomy	
Left-side mastectomy	
Right-side mastectomy	

Lumpectomy	
Other:	

5. Please state the following for EACH cancer diagnosis:

Type of Cancer	
Date of Diagnosis	
Primary Oncologist	Name: Address: Dates of Treatment: Treatment:
Primary Oncologist	Name: Address: Dates of Treatment: Treatment:
Primary Oncologist	Name: Address: Dates of Treatment: Treatment:
Treatment Facility	Name: Address: Dates of Treatment: Treatment:
Treatment Facility	Name: Address: Dates of Treatment: Treatment:
Treatment Facility	Name: Address: Dates of Treatment: Treatment:
Treatment Facility	Name: Address: Dates of Treatment: Treatment:

Type of Cancer	
Date of Diagnosis	
Primary Oncologist	Name: Address: Dates of Treatment: Treatment:

Type of Cancer	
Date of Diagnosis	
	Name:
Primary Oncologist	Address:
Timaly Offcologist	Dates of Treatment:
	Treatment:
	Name:
Drimany Oncologist	Address:
Primary Oncologist	Dates of Treatment:
	Treatment:
	Name:
Tuestment Feeilitz	Address:
Treatment Facility	Dates of Treatment:
	Treatment:
	Name:
T44 E:1:4	Address:
Treatment Facility	Dates of Treatment:
	Treatment:
	Name:
TD 4 4 TD 1124	Address:
Treatment Facility	Dates of Treatment:
	Treatment:
	Name:
TD 4 4 TD 2124	Address:
Treatment Facility	Dates of Treatment:
	Treatment:

Particulars of Chemotherapy

6.	When were you first diagnosed with the condition for which you were	
	prescribed Taxotere® or Docetaxel?	

7. What was the diagnosis for which you were prescribed Taxotere® or Docetaxel?

Diagnosis	Diagnosed
Breast cancer	
Non-small cell lung cancer	
Prostate cancer	
Gastric adenocarcinoma	
Head and neck cancer	
Other:	

8. For breast cancer, specify:

`	T	•
a)	Tumor	size:

Tumor Size	Yes
TX	
T0	
Tis	
T1	
T2	
T3	
T4 (T4a, T4b, T4c, T4d)	

h`	١	Metastasis:	
υ.	,	miciastasis.	

c) Node involvement:

Node	Yes
Node + NX	
Node + N0	
Node + N1	
Node + N2	
Node + N3	
Node – (negative)	

d)	HER2: + (positive): \square - (negative): \square
e)	Estrogen receptor: Positive (ER+): \square Negative (ER-): \square
f)	Progesterone receptor: Positive (PR+): ☐ Negative (PR-): ☐

9.	Was Taxotere® or Docetaxel the only chemotherapy treatment that you ever
	received? Yes □ No□ Unknown □

10.	Have you ever been treated with other chemotherapy drugs, either alone or in
	combination with or sequentially with Taxotere® or Docetaxel? Yes □ No□
	Unknown □

11. If yes, check which of the following chemotherapy drugs you took:

Drug	Yes
5-Fluorouracil (Eludex)	
Actinomycin	
Altretamine (Hexalen)	
Amsacrine	
Bleomycin	

Drug	Yes
Busulfan (Busulfex, Myleran)	
Cabazitaxel: Mitoxantrone	
Carboplatin (Paraplatin)	
Carmustine (BiCNU, Gliadel)	
Cetuximab (Erbitux)	
Chlorambucil (Leukeran)	
Cisplatin (Platinol)	
Cyclophosphamide (Neosar)	
Cytarabine (Depocyt)	
Dacarbazine	
Daunorubicin (Cerubidine, DaunoXome)	
Doxorubicin (Adriamycin, Doxil)	
Epirubicin (Ellence)	
Erlotinib (Tarceva)	
Etoposide (Etopophos, Toposar)	
Everolimus (Afinitor, Zortress)	
Faslodex (Fulvestrant)	
Gemcitabine (Gemzar)	
Hexamethylmelamine (Hexalen)	
Hydroxyurea (Hydrea, Droxia)	
Idarubicin (Idamycin)	
Ifosfamide (Ifex)	
L-asparginase (crisantaspase)	
Lomustine (Ceenu)	
Melphalan (Alkeran)	
Mercaptopurine (Purinethol, Purixan)	
Methotrexate (Trexall, Rasuvo)	
Mitomycin	
Mitoxantrone	
Nab-paclitaxel (Abraxane): Mitoxantrone	
Nitrogen mustard	
Paclitaxel (Taxol)	
Panitumumab (Vectibix)	
Procarbazine (Matulane)	
Sorafenib (Nexavar)	
Teniposide (Vumon)	
Thioguanine (Tabloid)	
Thiotepa (Tepadina)	
Topotecan (Hycamtin)	

Drug	Yes
Vemurafenib (Zelboraf)	
Vinblastine	
Vincristine (Mariqibo, Vincasar)	
Vindesine	
Vinorelbine (Alocrest, Navelbine)	
Unknown	

	Unkn	own
12.	Please	provide the following information regarding Taxotere® or Docetaxel:
	a)	Number of cycles:
	b)	Frequency: Every week \square Every three weeks \square Other:
	c)	First treatment date:
	d)	Last treatment date:
	e)	Dosage:
		(1) Combined with another chemotherapy drug: \Box
		(2) Sequential with another chemotherapy drug: \Box
		(3) If so, describe the combination or sequence:

13. Prescribing Physician(s):

Prescribing Physician	Address
	Street:
	City:
	State:
	Zip:
	Street:
	City:
	State:
	Zip:
	Street:
	City:
	State:
	Zip:

14. Treatment Facility:

Treatment Facility	Address	
	Street:	

			G:4		
			City: State:		
			Zip:		
			Street:		
			City:		
			State:		
			Zip:		
			Street: City:		
			State:		
			Zip:		
	15.	Identify EACH state where you Taxotere® or Docetaxel:			
		State	From Date	To D	ate
	17.	If yes, please provide the name a) Name of trial site:			
		b) Location of trial site:			
VI. CLAIM I	NF(ORMATION			
Current Status	S				
	1.	Are you currently taking Taxon	tere® or Docetaxe	l? Yes □ No	, 🗆
	2.	Are you currently cancer-free?	Yes □ No□		
	3.	If no, check those that apply to	your CURRENT	status:	
		Current Statu	ıs	Yes	
		In remission			
		Currently receiving chemothe	erapy		
		Currently receiving radiation	therapy		
		Currently hospitalized for can	icer or cancer-		
		related complications			

Currently in home health or hospice care for

Current Status	Yes
cancer or cancer-related complications	
Cancer returned after taking Taxotere® or Docetaxel	

4. When was the last (most recent) date you consulted with an oncologist:_____

Alleged Injury

5. State the injury you allege in this lawsuit and the dates between which you experienced the alleged injury. Check all that apply:

Persistent total alopecia – No hair growth on your head or body after six (6) months of discontinuing Taxotere® or Docetaxel treatment Persistent alopecia of your head – No hair growth on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment. Hair is present elsewhere on your body Permanent/Persistent Hair Loss on Scalp Diffuse thinning of hair: partial scalp Top Sides Back Temples Other: Diffuse thinning of hair: total scalp Top Sides Back Temples Other: Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Multiple bald spots in the hair on your head Multiple bald spots in the hair on your head	Alleged Injury	Yes	No	From	To
or Docetaxel treatment Persistent alopecia of your head – No hair growth on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment. Hair is present elsewhere on your body Permanent/Persistent Hair Loss on Scalp Diffuse thinning of hair: partial scalp Top Sides Back Temples Other: Diffuse thinning of hair: total scalp Top Sides Back Temples Other: Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head					
Persistent alopecia of your head – No hair growth on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment. Hair is present elsewhere on your body Permanent/Persistent Hair Loss on Scalp Diffuse thinning of hair: partial scalp	•				
your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment. Hair is present elsewhere on your body Permanent/Persistent Hair Loss on Scalp Diffuse thinning of hair: partial scalp					
Taxotere® or Docetaxel treatment. Hair is present elsewhere on your body Permanent/Persistent Hair Loss on Scalp Diffuse thinning of hair: partial scalp Sides Back Temples Other: Diffuse thinning of hair: total scalp Top Sides Back Temples Other: Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair on your head Large bald area in the hair on your head Large bald area in the hair on your head Large bald area in the hair on your head Large bald area in the hair on your head Large bald area in the hair on your head Large bald area in the hair on your head	•				
elsewhere on your body Permanent/Persistent Hair Loss on Scalp Diffuse thinning of hair: partial scalp Top Sides Back Temples Other: Diffuse thinning of hair: total scalp Top Sides Other: Diffuse thinning of hair: total scalp Top Sides Back Temples Other: Sides Back Temples Other: Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head		П			
Permanent/Persistent Hair Loss on Scalp Diffuse thinning of hair: partial scalp Top Sides Back Temples Other: Diffuse thinning of hair: total scalp Top Sides Back Temples Other: Diffuse thinning of hair: total scalp Top Sides Back Temples Other: Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head		_			
Diffuse thinning of hair: partial scalp Top Sides Back Temples Other: Diffuse thinning of hair: total scalp Top Sides Back Temples Other: Diffuse thinning of hair: total scalp Top Sides Back Temples Other: Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head					
☐ Top ☐ Sides ☐ Back ☐ Temples ☐ Other: ☐ Diffuse thinning of hair: total scalp ☐ Top ☐ Sides ☐ Back ☐ Temples ☐ Other: ☐ Sides ☐ Back ☐ Temples ☐ Other: ☐ Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐		Ш	Ш		
□ Sides □ Back □ Temples □ Other: □ Diffuse thinning of hair: total scalp □ Top □ Sides □ Back □ Temples □ Other: □ Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head □ □ □ □	Diffuse thinning of hair: partial scalp				
□ Back □ Temples □ Other: □ Diffuse thinning of hair: total scalp □ Top □ Sides □ Back □ Temples □ Other: □ Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head □ □ □ Large bald area in the hair on your head □ □ □	\square Top				
☐ Temples ☐ Other:	\square Sides				
□ Other: □ Diffuse thinning of hair: total scalp □ Top □ Sides □ Back □ Temples □ Other: □ Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment − There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment − There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head □ □ □	□ Back				
Diffuse thinning of hair: total scalp Top Sides Back Temples Other: Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head	☐ Temples				
☐ Top ☐ Sides ☐ Back ☐ Temples ☐ Other: ☐ Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐					
☐ Sides ☐ Back ☐ Temples ☐ Other:	Diffuse thinning of hair: total scalp				
□ Back □ Temples □ Other: Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head □ □ Large bald area in the hair on your head □ □ □	\square Top				
☐ Temples ☐ Other:	\square Sides				
Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head	□ Back	Ш	Ш		
Significant thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head	☐ Temples				
(6) months of discontinuing Taxotere® or Docetaxel treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head					
treatment – There are visible bald spots on your head no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head					
no matter how you style your hair Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head		П			
Moderate thinning of the hair on your head after six (6) months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head	treatment – There are visible bald spots on your head				
months of discontinuing Taxotere® or Docetaxel treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head					
treatment – There is noticeable hair loss but if you brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head	Moderate thinning of the hair on your head after six (6)				
brush or style your hair, the hair loss is less evident Small bald area in the hair on your head Large bald area in the hair on your head	months of discontinuing Taxotere® or Docetaxel				
Small bald area in the hair on your head Large bald area in the hair on your head □ □ □	treatment – There is noticeable hair loss but if you		ш		
Large bald area in the hair on your head	brush or style your hair, the hair loss is less evident				
	Small bald area in the hair on your head				
Multiple bald spots in the hair on your head	Large bald area in the hair on your head				
· · · · · · · · · · · · · · · · · · ·	Multiple bald spots in the hair on your head				

	Alleged Injur	v	Yes	No	From	T
	Change in the texture, thickness or				-	
	after Taxotere® or Docetaxel treats		Ш			
	Other:					
	Permanent/Persistent Loss of Eyebrows					
	Permanent/Persistent Loss of Eyelashes					
	Permanent/Persistent Loss of Body	y Hair				
	Permanent/Persistent Loss of Genital Hair					
	Permanent/Persistent Loss of Nasal Hair					
	Permanent/Persistent Loss of Ear l	Hair				
	Permanent/Persistent Loss of Hair Describe:	in Other Areas				
6.	Have you ever received treatment for □ No□ Name of Treating Physician	Dates of Treatmen			tments	
	Traine of Treating Thysician	Dates of Treatmen		IICa	iments	
7.	Were you diagnosed by a healthcare lawsuit? Yes □ No□					
	Name of Treating Physician	Dates of Treatmen	t	Trea	tments	
8.	Have you discussed with any healthc caused or contributed to your alleged		axotere	e [®] or l	Docetaxe	el
	Name of Treating Physician	Dates of Treatmen	t	Trea	tments	
Inform	ation					
9.	Were you ever given any written in packaging, package inserts, literature instructions, regarding chemotherap	re, medication guides,	or dos	ing		

Description	of Document		Have the ocuments	I Do Not Have the Documents
 Were you given any chemotherapy or you If yes, please identify instructions: 	r use of Taxotere® or	Docet	axel? Yes □] No□
Name of Heal	lthcare Provider			
3. Have you ever seen a commercials) for Tax4. If yes, identify the acsaw the advertisement	kotere® or Docetaxel? Ivertisement or comm	Yes [□No□	
commercials) for Tax4. If yes, identify the adsaw the advertisement	kotere® or Docetaxel? Ivertisement or comm	Yes [nercial,	No□ and approxi Date of A	
4. If yes, identify the act saw the advertisement	kotere® or Docetaxel? Ivertisement or communit or commercial:	Yes [nercial,	No□ and approxi Date of A	mately when you dvertisement or
4. If yes, identify the act saw the advertisement	kotere® or Docetaxel? Ivertisement or communit or commercial:	Yes [nercial,	No□ and approxi Date of A	mately when you dvertisement or
commercials) for Tax4. If yes, identify the adsaw the advertisement	votere® or Docetaxel? Ivertisement or comment or commercial: sement or Commercial: our attorneys, have your attorneys, have your attorneys or the interest	Yes Carried,	No□ and approxi Date of A Coi any communication	mately when you dvertisement or mmercial nication, oral or
4. If yes, identify the act saw the advertisement. Type of Advertisement. 5. Other than through y written, with any of the act of the commercials.	votere® or Docetaxel? Ivertisement or comment or commercial: sement or Commercial: our attorneys, have your attorneys, have your attorneys or the interest	Yes Enercial,	No□ and approxi Date of A Coi any communication	mately when you dvertisement or mmercial nication, oral or
commercials) for Tax 4. If yes, identify the act saw the advertisement Type of Advertisement 5. Other than through y written, with any of the control of	votere® or Docetaxel? Ivertisement or comment or commercial: sement or Commercial: our attorneys, have your attorneys, have your attorneys or the Defendants or the Defenda	Yes Enercial,	and approxi Date of A Con any communicatives?	mately when you dvertisement or mmercial nication, oral or Yes □ No□

YOU MUST UPLOAD NOW ANY MEDICAL RECORDS IN YOUR POSSESSION DEMONSTRATING ALLEGED INJURY OR PHOTOGRAPHS SHOWING YOUR HAIR BEFORE AND AFTER TREATMENT WITH TAXOTERE® ALONG WITH THE DATE(S) THE PHOTOGRAPHS WERE TAKEN.

Other	Claimed	Damages
-------	---------	----------------

I	18. Mental or Emotional Damages: Do you claim that your use of Taxotere [®] or Docetaxel caused or aggravated any psychiatric or psychological condition? Yes □ No□					
	If yes, did you seek treatmen Yes □ No□	t for the psychiat	ric or psychological condition?			
	Provider	Date	Condition			
Ī						
21. I	alleged injury that you claim No□ If yes, list all of your medica	was caused by T l expenses, include payors, which as	ding amounts billed or paid by re related to any alleged injury			
_						
	Provider	Date	Expense			
	Provider	Date				
	Provider	Date				
	Provider	Date				
22. I	Lost Wages: Do you claim the carning capacity because of the Caxotere® or Docetaxel? Yes	nat you lost wage: the alleged injury to \(\subseteq \text{No} \subseteq \) income you earno	Expense s or suffered impairment of that you claim was caused by ed for each of the three (3) years			
22. I	Lost Wages: Do you claim the earning capacity because of the Taxotere® or Docetaxel? Yes aff yes, state the annual gross	nat you lost wage: the alleged injury to \(\subseteq \text{No} \subseteq \) income you earno	Expense s or suffered impairment of that you claim was caused by ed for each of the three (3) years xotere® or Docetaxel.			
22. I 6 7 23. I 8 1 24. \$ 24. \$	Lost Wages: Do you claim the earning capacity because of the Taxotere® or Docetaxel? Yes a state the annual gross before the injury you claim the taxon of the earn of the taxon of the earn of the ea	nat you lost wages the alleged injury to No income you earnor vas caused by Tax Annual Gros	Expense s or suffered impairment of that you claim was caused by ed for each of the three (3) years xotere® or Docetaxel. ss Income			

25. Out-of-Pocket Expenses: Are you making a claim for lost out-of-expenses? Yes □ No□ 26. If yes, please identify and itemize all out-of-pocket expenses you incurred: Expense Expense Amount	-
expenses? Yes No 26. If yes, please identify and itemize all out-of-pocket expenses you incurred: Expense Expense Amount VII. HAIR LOSS INFORMATION	-
expenses? Yes No 26. If yes, please identify and itemize all out-of-pocket expenses you incurred: Expense Expense Amount VII. HAIR LOSS INFORMATION	-
expenses? Yes No 26. If yes, please identify and itemize all out-of-pocket expenses you incurred: Expense Expense Amount VII. HAIR LOSS INFORMATION	-
Expense Expense Amount VII. HAIR LOSS INFORMATION	u have
VII. HAIR LOSS INFORMATION	
Rackground	
1. Did you ever see a healthcare provider for hair loss BEFORE tak	king
Taxotere® or Docetaxel? Yes ☐ No ☐	C
2. Did your hair loss begin during chemotherapy treatment? Yes □	J No⊔
3. If yes, did you FIRST experience hair loss:	
a) After treatment with another chemotherapy agent: \Box	
b) After treatment with Taxotere [®] or Docetaxel: \square	
4. At any time before or during the hair loss were you:	
Condition Yes Description	on
Pregnant	
Seriously ill	
Hospitalized	
Under severe stress	
Undergoing treatment for any	
_411	
other medical condition	
5. When did you FIRST discuss with or see a healthcare provider a loss?	bout your
5. When did you FIRST discuss with or see a healthcare provider a loss?	
5. When did you FIRST discuss with or see a healthcare provider a	he hair loss

Hair Loss History

Question		No	Yes	Name of Healthcare Provider
Have you had a biopsy of your scalp your hair loss problem?				
Have you had blood tests done to evaloss problem?				
Have your hormones ever been checkyour hair loss problem?	ked to evaluate			
Have you ever been told by a doctor thyroid condition?				
Have you ever been treated with thyroid hormone?				
Have you ever been told by a doctor that you have a low iron level?				
 7. Have you ever been on endoor chemotherapy with Taxotere® 8. If yes, please identify: 				re or after

9. Do you have any autoimmune diseases? Yes	\square No \square

10. If yes, check the following which describes you:

Autoimmune Disease	Yes
Lupus	
Rheumatoid arthritis	
Celiac disease	
Type 1 diabetes	
Sjogrens disease	
Vitiligo	
Hashimoto's	
Other:	

11. Were you taking any medications when your hair loss began? Yes \square No \square

Medication

Hair Care

- 12. How often do you wash/shampoo your hair? Every _____ days
- 13. Check any of the following that apply to you currently or that have in the past:

Hair Treatment	Yes	Period of Time	Frequency
			☐ Never
Hair chemically processed or			☐ Once a week
straightened (relaxers, keratin,	Ιп		☐ 2-3 times a week
Brazilian blowout, Japanese			☐ Once a month
straightening, other)			\square Once every 1-2 months
			☐ A few times a year
			☐ Never
Hein heat muceased on			☐ Once a week
Hair heat processed or straightened (blow drying/ flat	Ιп		\square 2-3 times a week
ironing, curling)			☐ Once a month
			\square Once every 1-2 months
			☐ A few times a year
			□ Never
			☐ Once a week
Hair dyed	Ιп		\square 2-3 times a week
Train dyed			☐ Once a month
			\square Once every 1-2 months
			☐ A few times a year
			☐ Never
			☐ Once a week
Hair highlighted			\square 2-3 times a week
Than inginighted			☐ Once a month
			\square Once every 1-2 months
			☐ A few times a year
			☐ Never
			☐ Once a week
Braids	Ιп		☐ 2-3 times a week
Diaids			☐ Once a month
			☐ Once every 1-2 months
			☐ A few times a year

					ш	Office a week
	Weaves	П				2-3 times a week
	weaves	Ш				Once a month
						Once every 1-2 months
						A few times a year
						Never
						Once a week
	T' 1 (1 ' () () () ()					2-3 times a week
	Tight hairstyles (ponytails)					Once a month
						Once every 1-2 months
						A few times a year
						Never
						Once a week
						2-3 times a week
	Extensions	Ш				Once a month
						Once every 1-2 months
						A few times a year
						Never
						Once a week
						2-3 times a week
	Other:	Ш				Once a month
						Once every 1-2 months
						A few times a year
14. H	Have you ever used the following?					
	Hair Treatment			Yes		
	WEN Cleansing Conditioners					
	Unilever Suave Professionals Keratin Infusion					
	L'Oréal Chemical Relaxer					
15. H	Has your hair care regimen been di	fferent	in the p	ast? Ye	s 🗆	□ No□
	a) If yes, describe:					
Hair Loss Treatmen						

□ Never

24

16. Did you use any other methods to prevent hair loss during chemotherapy?

	Hair Treatmer	nt	Yes				
	Folic Acid supplementation						
	Minoxidil						
	Other:						
17.	17. Did you wear a cool cap during chemotherapy treatment? Yes \square No \square						
18.	18. If yes, which cooling cap did you wear:						
	19. Have you used any over-the-counter medications, supplements, or cosmetic aides for your hair loss? Yes □ No□						
20.	If yes, please state the following	j:					
	Treatment	When was it tried?	How long did you try it?	Did it help?			
				☐ Yes			
				□ No			
				☐ Yes			
				□ No □ Yes			
				□ No			
	Has anything helped your hair least least least least specify:	oss? Yes □ N	о□				
	Type of Product	Dates of Use	Place of Purchase	Results of Use			
23. As of the date you verify your PFS, how long have you had alopecia or incomplete hair re-growth?							
24.	Has any hair regrowth occurred	? Yes □ No□]				
25.	Have you ever worn a wig to co	onceal your hai	r loss? Yes □ 1	No□			
26.	Specify:						

Dates Used	Period of Use	Place Purchased	Cost of Item

VIII. RECORD HOLDER IDENTIFICATION

Healthcare Providers:

1. Identify each physician, doctor, or other healthcare provider who has provided treatment to you for any reason in the past eight (8) years and the reason for consulting the healthcare provider or mental healthcare provider.

YOU MUST INCLUDE YOUR ONCOLOGIST, RADIOLOGIST, DERMATOLOGIST, DERMATOLOGIST, HAIR LOSS SPECIALIST, GYNECOLOGIST, OBSTETRICIAN, AND PRIMARY CARE PHYSICIAN, ALONG WITH ANY OTHER HEALTHCARE PROVIDERS IDENTIFIED ABOVE

Name	Area or Specialty	Address	Dates	Reason for Consultation

Hospitals, Clinics, and Other Facilities:

2. Identify each hospital, clinic, surgery center, physical therapy or rehabilitation center, or other healthcare facility where you have received inpatient or outpatient treatment (including emergency room treatment) in the past eight (8) years:

YOU MUST INCLUDE THE LOCATIONS FOR SURGERIES, RADIOLOGY, IMAGING, BIOPSIES, CHEMOTHERAPY, CHILD BIRTHS, GYNECOLOGIC PROCEDURES OR TREATMENT, ALONG WITH ANY OTHER HEALTHCARE FACILITIES

Name	Address	Dates	Reason for Treatment

Laboratories:

3. Identify each laboratory at which you had tests run in the past ten (10) years:

Name	Address	Dates	Test	Reason for Tests

Pharmacies:

4. To the best of your recollection, Identify each pharmacy, drugstore, and/or other supplier (including mail order) where you have had prescriptions filled or from which you have ever received any prescription medication within three (3) years prior to and three (3) years after your first treatment with Taxotere:

Name	Address	Dates	Medications

Retailers:

5. Identify each pharmacy, drugstore, and/or other retailer (including mail order) where you have purchased over-the-counter medications, or hair products in the past ten (10) years:

Name	Address	Dates	Purchases

Insurance Carriers:

6. Identify each health insurance carrier which provided you with medical coverage and/or pharmacy benefits for the last ten (10) years:

Carrier	Address	Name of Insured & SSN	Policy Number	Dates of Coverage

IX. DOCUMENT REQUESTS AND AUTHORIZATIONS

Please state which of the following documents you have in your possession. If you do not have the following documents but know they exist in the possession of others, state who has possession of the documents: Produce all documents in your possession (including writings on paper or in electronic form) and signed authorizations and attach a copy of them to this PFS.

Requests

Type of Document(s)	Yes	No	If No, who has the document(s)?
Documents you reviewed to prepare your answers to this			
Plaintiff Fact Sheet.			
Your attorney may withhold some documents on claims of			
attorney-client privilege or work product protection and,			
if so, provide a privilege log			
Medical records or other documents related to the use of			
Taxotere® or Docetaxel at any time for the past twelve			
(12) years.			
Medical records or other documents related to your			
treatment for any disease, condition or symptom			
referenced above for any time in the past twelve (12)	Ш		
years.			
Laboratory reports and results of blood tests performed		П	
on you related to your hair loss.	Ш		
Pathology reports and results of biopsies performed on			
you related to your hair loss.			
Plaintiffs or their counsel must maintain the slides and/or			
specimens requested in this subpart, or send a	Ш		
preservation notice, copying Defendants, to the			
healthcare facility where these items are maintained.			
Documents reflecting your use of any prescription drug		П	
or medication at any time within the past eight (8) years.			
Documents identifying all chemotherapy agents that you	П	П	
have taken.			
Documents for any workers' compensation, social			
security or other disability proceeding at any time within			
the last five (5) years.			
Instructions, product warnings, package inserts, handouts			
or other materials that you were provided or obtained in			
connection with your use of Taxotere®.			
Advertisements or promotions for Taxotere®.			
Articles discussing Taxotere [®] .			

Type of Document(s)	Yes	No	If No, who has the document(s)?
Any packaging, container, box, or label for Taxotere® or Docetaxel that you were provided or obtained in connection with your use of Taxotere®. Plaintiffs or their counsel must maintain the originals of these items.			
Documents which mention Taxotere® or Docetaxel or any alleged health risks related to Taxotere®. Your attorney may withhold some legal documents, documents provided by your attorney, or documents obtained or created for the purpose of seeking legal advice or assistance on claims of attorney-client privilege or work product protection and, if so, provide a privilege log.			
Documents obtained directly or indirectly from any of the Defendants.			
Communications or correspondence between you and any representative of the Defendants.			
Photographs, drawing, slides, videos, recordings, DVDs, or any other media that show your alleged injury or its effect in your life.			
Journals or diaries related to the use of Taxotere® or Docetaxel or your treatment for any disease, condition or symptom referenced above at any time for the past twelve (12) years.			
Social media or internet posts to or through any site (including, but not limited to, Facebook, MySpace, LinkedIn, Google Plus, Windows Live, YouTube, Twitter, Instagram, Pinterest, blogs, and Internet chat rooms/message boards) relating to Taxotere® or Docetaxel or any of your claims in this lawsuit.			
If you claim you have suffered a loss of earnings or earning capacity, your federal tax returns for each of the five (5) years preceding the injury you allege to be caused by Taxotere® or Docetaxel, and every year thereafter or W-2s for each of the five (5) years preceding the injury you allege to be caused by Taxotere® or Docetaxel, and every year thereafter.			
If you claim any medical expenses, bills from any physician, hospital, pharmacy or other healthcare providers.			
Records of any other expenses allegedly incurred as a result of your alleged injury.			
If you are suing in a representative capacity, letters testamentary or letters of administration.			

Type of Document(s)	Yes	No	If No, who has the document(s)?
If you are suing in a representative capacity on behalf of a deceased person, decedent's death certificate and/or		П	
autopsy report.			
Photographs of you that are representative of your hair			
composition before treatment with Taxotere® or			
Docetaxel.			
Photographs of you that are representative of your hair	_		
composition during treatment with Taxotere® or			
Docetaxel.			
Photographs of you that are representative of your hair			
composition six months after conclusion of treatment			
with Taxotere® or Docetaxel.			
Photographs of you that are representative of your hair			
composition in present day.			
Signed authorizations for medical records related to any			
cancer treatment identified herein and all pharmacy			
records from three (3) years before and three (3) years			
after your first treatment with Taxotere in the forms attached hereto.			
attached hereto.			
X. DECLARATION			
Pursuant to 28 U.S.C. § 1746, I declare under information provided in connection with this Plain	tiff Pro	file For	= =

Pursuant to 28 U.S.C. § 1746, I decla	ire under penalt	y of perjury	that all of the
information provided in connection with t	his Plaintiff Prof	ile Form is tru	ue and correct to
the best of my knowledge information and	belief at the pres	ent time.	

Signature Date

XI. AUTHORIZATIONS

See Attached Exhibit A.

LIMITED AUTHORIZATION TO DISCLOSE HEALTH INFORMATION

<u>Pursuant to the Health Insurance Portability and Accountability Act "HIPAA" of 4/14/03</u> (Excluding Psychiatric, Psychological, and Mental Health Treatment Notes/Records)

TO: Patient Name: DOB: SSN:
I,, hereby authorize you to release and furnish to: Shook Hardy & Bacon LLP, Keogh Cox Wilson Ltd., Ulmer & Berne LLP, Greenberg Traurig LLP, Wheeler Trigg O'Donnell LLP, Adams and Reese LLP, Chaffe McCall LLP Quinn Emanuel Urquhart & Sullivan LLP, Morrison & Foerster LLP, Leake & Anderson LLP, Hinshaw & Culbertson LLP, Kirkland & Ellis LLP and/or their duly assigned agents, copies of the following records and/or information from the time period of twelve (12) year prior to the date on which the authorization is signed:
* All medical records, including inpatient, outpatient, and emergency room treatment, all clinical charts, reports, documents, correspondence, test results, statements, questionnaires/histories, office and doctor's handwritten notes, and records received by other physicians. Said medical records shall include all information regarding AIDS and HIV status. * All autopsy, laboratory, histology, cytology, pathology, radiology, CT Scan, MRI, echocardiogram and cardiac catheterization reports. * All radiology films, mammograms, myelograms, CT scans, photographs, bone scans, pathology/cytology/histology/autopsy/immunohistochemistry specimens, cardiac catheterization videos/CDs/films/reels, and echocardiogram videos. * All pharmacy/prescription records including NDC numbers and drug information handouts/monographs. * All billing records including all statements, itemized bills, and insurance records. **Notwithstanding the broad scope of the above disclosure requests, the undersigned does not authorize the disclosure of notes of records pertaining to psychiatric, psychological, or mental health treatment or diagnosis as such terms are defined by HIPAA, 4 CFR §164.501.
1. To my medical provider: this authorization is being forwarded by, or on behalf of, attorneys for the defendants for the purpose of litigation. You are not authorized to discuss any aspect of the above-named person's medical history, care, treatment, diagnosis, prognosis, information revealed by or in the medical records, or any other matter bearing on his or her medical or physical condition, unless you receive an additional authorization permitting such discussion. Subject to all applicable legal objections, this restriction does not apply to discussing my medical history, care, treatment, diagnosis, prognosis, information revealed by or in the medical records, or any other matter bearing on my medical or physical condition at a deposition or trial.
2. I understand that the information in my health record may include information relating to sexually transmitted disease, acquired immunodeficiency syndrome (AIDS), or human immunodeficiency virus (HIV).
3. I understand that I have the right to revoke this authorization at any time. I understand that if I revoke this authorization I must do so in writing and present my written revocation to the health information management department. I understand the revocation will not apply to information that has already been released in response to this authorization. I understand the revocation will not apply to my insurance company when the law provides my insurer with the right to contest a claim under my policy. Unless otherwise revoked, this authorization will expire in one year.
4. I understand that authorizing the disclosure of this health information is voluntary. I can refuse to sign this authorization. I need not sign his form in order to assure treatment. I understand I may inspect or copy the information to be used or disclosed as provided in CFR 164.524. I understand that any disclosure of information carries with it the potential for an unauthorized re-disclosure and the information may not be protected by federal confidentiality rules. If I have questions about disclosure of my health information, I can contact the releaser indicated above.
5. A notarized signature is not required. CFR 164.508. A copy of this authorization may be used in place of an original.
Print Name:(plaintiff/representative)

Signature: ___

LIMITED AUTHORIZATION TO DISCLOSE EMPLOYMENT RECORDS AND INFORMATION (HIPAA COMPLIANT AUTHORIZATION FORM PURSUANT TO 45 CFR 164.508)

TO:					
	Name of Employer				
	Address, City State and Zip Cod	e			
RE:	Employee Name:	_	AKA:		
	Date of Birth:	Social Secu	rity Number:		
	Address:				
45 CF	orize the <u>limited</u> disclosure of my emR 164.508, for the purpose of review	w and evaluation in conf	nection with a legal c	laim.	
years _] above	uthorization only authorizes release prior to the date on which this as disclose full and complete records ization is signed, including the follows:	uthorization is signed. from the time period of	I expressly request t	hat all entities identified	
held; j increas	vill authorize you to furnish copies job descriptions of positions held ses and decreases; evaluations, review pondence and memoranda regarding	; wage and income star ews and job performance	tements and/or comp	pensation records; wage	
I auth	orize you to release the information	1 to:			
Name	e (Records Requestor)	_	_		
Street	Address	City		State and Zip Code	
learne	nd that this authorization shall be coed or discovered at any time in the fecords Requestor at that time.				
under will n	nowledge the right to revoke this au stand that any actions already taker of affect those actions. Any facsimic cords herein.	n in reliance on this auth	orization cannot be re	eversed, and my revocation	
Signa	ture of Employee or Personal Repr	esentative Date	Name of Employ	ree or Personal Representative	
Descr	ription of Personal Representative's	Authority to Sign for E	nployee (attach docu	ments that show authority)	

LIMITED AUTHORIZATION FOR RELEASE OF WORKERS' COMPENSATION RECORDS

To:			
10.	Name		
	Address		
	City, State and Zip Code		
	thorize you to furnish copies of any and all workers' compensation records		
•	y workers' compensation claims filed within the last ten (10) years,		
•	limited to, statements, applications, disclosures, correspondence, notes,		
settlements, agree	ements, contracts or other documents, concerning:		
	Name of Claimant		
whose date of bir	th isand whose social security number is		
You are au defendants in the a supply copies of su	thorized to release the above records to the following representatives of bove-entitled matter, who have agreed to pay reasonable charges made by you to ach records.		
Name of Representative			
Records Re	equestor		
	ative Capacity (e.g., attorney, records requestor, agent, etc.)		
Street Add	lress		
City, State	e and Zip Code		

This authorization only authorizes release of documents and records from the period of ten (10) years prior to the date on which this authorization is signed. This authorization does not authorize you to disclose anything other than documents and records to anyone.

This authorization shall be considered as continuing in nature and is to be given full force
and effect to release information of any of the foregoing learned or determined after the date hereof.
It is expressly understood by the undersigned and you are authorized to accept a copy or photocopy
of this authorization with the same validity as through the original had been presented to you.
Date: Claimant Signature
[NAME]

Witness Signature

Date:

LIMITED AUTHORIZATION FOR RELEASE OF DISABILITY CLAIMS RECORDS

To:				
	Name			
	Address			
	Address			
	City, State and Zip Code			
This wil	l authorize you to furnish copies of any and all records of disability claims of any			
sort for any dis	ability claim(s) filed within the last ten (10) years, including, but not limited to,			
statements, appl	ications, disclosures, correspondence, notes, settlements, agreements, contracts or			
other documents	s, concerning:			
	Name of Claimant			
whose date of	birth isand whose social security number is			
You are	authorized to release the above records to the following representatives of			
defendants in th	e above-entitled matter, who have agreed to pay reasonable charges made by you to			
supply copies of	f such records.			
You are	authorized to release the above records to the following representatives of			
lefendants in the above-entitled matter, who have agreed to pay reasonable charges made by you to				
supply copies of	f such records.			
Name o	f Representative			
Records	Requestor			
Represe	entative Capacity (e.g., attorney, records requestor, agent, etc.)			
Street A	Address			
City, State and Zip Code				

This authorization only authorizes release of documents and records from the period of ten				
(10) years prior to the date on which this authorization is signed. This authorization does not				
authorize you to disclose anything other than documents and records to anyone.				
Date:	Claimant Signature [NAME]			
Date:	Witness Signature			

FOR RELEASE OF HEALTH INSURANCE RECORDS

To:	
	Name
	Address
	City, State and Zip Code
This will autho	orize you to furnish copies of any and all insurance claims applications and
benefits, and all medic	eal, health, hospital, physicians, nursing or allied health professional reports,
records or notes, invoi	ces and bills, in your possession that pertain to the named insured identified
below. This authoriz	ation only authorizes release of Health Insurance records and/or
information from the	e time period of ten (10) years prior to the date on which this authorization
is signed.	
	Name of Claimant
whose date of birth is	sand whose social security number is
You are author	rized to release the above records to the following representatives of
defendants in the abov	re-entitled matter, who have agreed to pay reasonable charges made by you to
supply copies of such	records.
Name of Repr	resentative
Records Reque	estor
	ve Capacity (e.g., attorney, records requestor, agent, etc.)
Street Addres	SS S
City, State an	d Zip Code

This authorization only authorizes release of documents and records from the period of ten (10) years prior to the date on which this authorization is signed. This authorization does not authorize you to disclose anything other than documents and records to anyone.

This authorization is not valid unless the record requestor named above has executed the acknowledgement at the bottom of this authorization.

This authorization shall be considered as continuing in nature and is to be given full force and effect to release information of any of the foregoing learned or determined after the date hereof. It is expressly understood by the undersigned and you are authorized to accept a copy or photocopy of this authorization with the same validity as through the original had been presented to you.

Date:	Claimant Signature [NAME]
Date:	Witness Signature

LIMITED AUTHORIZATION TO DISCLOSE PSYCHIATRIC, PSYCHOLOGICAL AND/OR MENTAL HEALTH TREATMENT NOTES/RECORDS (Pursuant to the Health Insurance Portability and Accountability Act "HIPAA" of 4/14/03)

Signatu	: Date
Print Na	ne: (plaintiff/representative)
5. A n	tarized signature is not required. CFR 164.508. A copy of this authorization may be used in place of an original.
3. I ur so in wr not appl my insu this auth 4. I ur not sign in CFR informa	erstand that I have the right to revoke this authorization at any time. I understand that if I revoke this authorization I must do ing and present my written revocation to the health information management department. I understand the revocation will to information that has already been released in response to this authorization. I understand the revocation will not apply to note company when the law provides my insurer with the right to contest a claim under my policy. Unless otherwise revoked rization will expire in one year. erstand that authorizing the disclosure of this health information is voluntary. I can refuse to sign this authorization. I need is form in order to assure treatment. I understand I may inspect or copy the information to be used or disclosed as provided 54.524. I understand that any disclosure of information carries with it the potential for an unauthorized re-disclosure and the on may not be protected by federal confidentiality rules. If I have questions about disclosure of my health information, I car e releaser indicated above.
immunc	erstand that the information in my health record may include information relating to sexually transmitted disease, acquired eficiency syndrome (AIDS), or human immunodeficiency virus (HIV). It may also include information about behavioral or alth services, and treatment for alcohol and drug abuse.
defenda history health an addi apply t by or i	by medical and/or mental health provider: this authorization is being forwarded by, or on behalf of, attorneys for the dist for the purpose of litigation. You are not authorized to discuss any aspect of the above-named person's medical mental health history, care, treatment, diagnosis, prognosis, information revealed by or in the medical or mental cords, or any other matter bearing on his or her medical, psychological, or physical condition, unless you receive onal authorization permitting such discussion. Subject to all applicable legal objections, this restriction does not discussing my medical history, mental health history, care, treatment, diagnosis, prognosis, information revealed the medical or mental health records, or any other matter bearing on my medical, psychological, or physical at a deposition or trial.
•	All "psychotherapy notes", as such term is defined by the Health Insurance Portability and Accountability Act, 45 CFR (164.501. Under HIPAA, the term "psychotherapy notes" means notes recorded (in any medium) by a health care provider who is a mental health professional documenting or analyzing the contents of conversations during a private counseling session are group, joint or family counseling session and that are separated from the rest of the individual's record. This authorization loes not authorize ex parte communication concerning same.
	, hereby authorize you to release and furnish to: Shook Hardy & Bacon LLP, Keogh Cox & Wilson Ltd., Ulmer & Berne LLP, Greenberg Traurig LLP, Wheeler Trigg O'Donnell LLP, Adams and Reese LLP, Chaffe McCall LLP, Quinn Emanuel Urquhart & Sullivan LLP, Morrison & Foerster LLP, Leake & Anderson LLP, Hinshaw & Culbertson LLP, Kirkland & Ellis LLP and/or their duly assigned agents, copies of the following records and/or information from the time period of ten (10) years prior to the date on which the authorization is signed:
TO: Patient l DOB: SSN:	ame:

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

IN RE: TAXOTERE (DOCETAXEL)	MDL NO. 2740
PRODUCTS LIABILITY LITIGATION	SECTION "N" (5)
THIS DOCUMENT RELATES TO:	
ALL CASES	HON. KURT D. ENGELHARDT

DEFENDANT FACT SHEET – PRODUCT IDENTIFICATION

Within seventy-five (75) days of receiving a substantially completed Plaintiff Fact Sheet ("PFS"), Defendants Sanofi S.A., Aventis Pharma S.A., and Sanofi-Aventis U.S., LLC, and Winthrop US (collectively referred to as "Defendants") must complete and serve this Defendant Fact Sheet ("DFS") and identify or provide DOCUMENTS and/or data responsive to the questions set forth below for each such Plaintiff. Defendants must supplement their responses to the extent that additional information is provided by Plaintiff in a supplemental PFS, within sixty (60) days of receiving the supplemental information. In the event the DFS does not provide YOU with enough space to complete YOUR responses or answers, please attach additional sheets if necessary. Please identify any DOCUMENTS that YOU are producing as responsive to a question or request by bates number.

DEFINITIONS & INSTRUCTIONS

As used herein, "YOU," "YOUR," or "YOURS" means the responding DEFENDANTS.

"DEFENDANTS" shall mean and refer to those companies involved in the development, manufacture and distribution of the drugs known as Taxotere (Docetaxel) including Sanofi S.A., Aventis Pharma S.A., Sanofi-Aventis U.S., LLC, and Winthrop US shall each answer each document request and question that not only calls for YOUR knowledge, but also for all knowledge that is available to YOU by reasonable inquiry, including inquiry of YOUR "officers," "directors," "agents," "employees," and attorneys.

As used herein, the phrase "HEALTHCARE PROVIDER" means: any physician or other individual healthcare provider, health care facility, clinic, hospital or hospital pharmacy identified by full name and address in PFS Section Sections V.13 and V.14 who administered, prescribed, and/or dispensed Taxotere (Docetaxel) to the Plaintiff.

"REMUNERATION" means anything of value, directly or indirectly, overtly or covertly, in cash or in kind, including but not limited to monetary payment, compensation, incentives, preceptorship fees, gifts, entertainment, sports and/or concert tickets, speaker fees, grants, SAMPLES, reimbursement assistance, beneficiary inducements, wellness programs, patience assistance

programs, transportation and/or lodging assistance, adherence to treatment regimen programs, incentives or inducements to remain in network, navigator/care coordination programs, end of life and/or palliative care programs, third party payments of premiums, or any other inducements or programs.

As used herein, the term "DOCUMENT" shall, consistent with Federal Rule of Civil Procedure 34(a)(1)(A), refer to any "designated documents or electronically stored information – including writings, drawings, graphs, charts, photographs, sound recordings, images, and other data or data compilations – stored in any medium form which information can be obtained either directly or, if necessary, after translation by the responding party into a reasonably usable form."

If YOU are aware that any DOCUMENT that was, or might have been, responsive to any sections of this DFS which concern or relate to Plaintiff or Plaintiff's Named Facilities was destroyed, erased, surrendered or otherwise removed from YOUR possession, custody or control, at any time, provide, to the maximum extent possible, the following information: (a) the nature of the DOCUMENT (e,g., letter, memorandum, contract, etc.,) and a description of its subject matter; (b) the author or sender of the DOCUMENT; (c) the recipient(s) of the DOCUMENT; (d) the date that the DOCUMENT was authored, sent and received; (e) the circumstances surrounding the removal of the DOCUMENT from YOUR custody, possession or control; and (f) the identity of the person(s) having knowledge of such removal from YOUR custody, possession or control.

As used herein, "KEY OPINION LEADER" or "THOUGHT LEADER" shall mean and refer to physicians, often academic researchers, who are believed by DEFENDANTS to be effective at transmitting messages to their peers and others in the medical community. This term shall mean and refer to any doctors or medical professionals hired by, consulted with, or retained by DEFENDANTS to, amongst other things, consult, give lectures, respond to media inquiries, conduct clinical trials, write articles or abstracts, sign their names as authors to articles or abstracts written by others, sit on advisory boards and make presentations on their behalf at regulatory meetings or hearings.

The phrase "SAMPLES" refers to any medication or unit of a prescription drug not intended to be sold, which is given to promote the drug's sales. This includes any vouchers or coupons that provide for the HEALTHCARE PROVIDERS or patients access to the medication for a specified period of time.

"PATIENT ASSISTANCE PROGRAM" means programs created by drug companies, such as Sanofi, to offer free or low cost drugs to individuals who are unable to pay for their medication. These Programs may also be called indigent drug programs, charitable drug programs or medication assistance programs.

The phrase "SALES REPRESENTATIVE" means any person presently or formerly engaged or employed by YOU whose job duties include calling on physicians or other health care professionals, healthcare facilities, hospitals, and/or physician practice groups; promoting drugs manufactured or licensed by YOU to physicians or other HEALTH CARE PROVIDERS; distributing drug SAMPLES to physicians or other HEALTH CARE PROVIDERS. "SALES REPRESENTATIVE" also includes those who occupy positions titled "Professional Sales Representative," "Sales Professional," "Specialty Sales Representative," "Senior Sales

Representative," "Senior Health Care Representative," "Professional Representative," "Health Care Representative," "Institutional" or "Managed Care" sales representative, "Oncology Sales Representative," "Medical Service Representative," and "Medical Sales Representative" or any other titles used by Defendants and any of its divisions SALES REPRESENTATIVE also includes any contract employees or SALES REPRESENTATIVES from other companies involved in the promotion or co-promotion of Taxotere (Docetaxel) .

The phrase "SALES MANAGER" means any person presently or formerly engaged or employed by YOU whose job duties include managing SALES REPRESENTATIVES and/or the promotion or marketing of pharmaceutical products in a specific geographic region. "SALES MANAGER" includes those who occupy positions titled "District Sales Manager," "Senior Regional Sales Manager," "Regional Sales Manager," "Area Business Manager," "Business Manager," or any other titles YOU use or have used in the past for managers involved in the promotion or marketing of Taxotere (Docetaxel).

The phrase "MEDICAL SCIENCE LIAISON(S)" means any person presently or formerly engaged or employed by YOU for the purpose of sales support and direct field communication with physicians or other HEALTH CARE PROVIDERS about medical and science information related to Taxotere (Docetaxel), and opinion leader management. This includes employees with the titles of "Medical Science Liaison (MSL)," "Clinical Education Consultant (CEC)" or any other titles YOU use or have used in the past for these employees.

The phrase "MARKETING ORGANIZATION REPRESENTATIVE," means any person presently or formerly engaged or employed by YOU for the purpose of generating interest in Taxotere (Docetaxel) by creating and implementing a marketing campaign(s) to reach physicians or other HEALTHCARE PROVIDERS. This includes employees with the title of "Marketing Representative" or any other titles YOU use or have used in the past for these employees.

The phrase "CALL NOTES" means any and all writings, notations, electronically stored information, memoranda, DOCUMENTS, emails, database entries and reports or records, internal communications and any other information reflecting any contact with HEALTHCARE PROVIDERS, and/or information about or referring to HEALTHCARE PROVIDERS related to Taxotere (Docetaxel), oncology, or the treatment of cancer and chemotherapy.

The phrase "TARGETING INFORMATION" means any information the company uses to identify a particular person, group of people, type of health care provider or demographic within a larger audience regarding the promotion of Taxotere (Docetaxel). This includes documentation, including electronically stored information, designating particular campaigns, PROMOTIONAL MATERIAL and/or other promotional efforts directed toward particular types or specialties of healthcare providers (e.g., oncologists) and/or specifically identified healthcare providers.

I. CASE INFORMATION

ivil Action No fourt in which action was of the this DFS was completed. ALE OF TAXOTERE (INTERPRETALIZED COMPLETALIZED C	deliver or otherwise provide	ER ROUGH GROUP
ourt in which action was of the control of the cont	ed: DOCETAXEL) TO DISPENSE Y) DIRECTLY AND/OR THE ZATIONS deliver or otherwise provide	ER ROUGH GROUP
Pate this DFS was completed. ALE OF TAXOTERE (INTERPRE) HOSPITAL/PHARMAC URCHASING ORGANI Pid YOU sell, distribute, HEALTHCARE PROVID	ed: DOCETAXEL) TO DISPENSE Y) DIRECTLY AND/OR THE IZATIONS deliver or otherwise provide	ER ROUGH GROUP
ALE OF TAXOTERE (IN TAXOTERE) (IN TAXOTERE (IN TAXOTERE (IN TAXOTERE) (IN TAXOTERE (IN TAXOTERE) (IN TAXOTERE (IN TAXOTERE) (IN TAXOTERE (IN TAXOTERE) (IN TAXOTERE) (IN TAXOTERE (IN TAXOTERE) (IN TAXOTERE) (IN TAXOTERE (IN TAXOTERE) (IN	DOCETAXEL) TO DISPENSE Y) DIRECTLY AND/OR THE ZATIONS deliver or otherwise provide	ER ROUGH GROUP
HOSPITAL/PHARMAC URCHASING ORGANI bid YOU sell, distribute, EALTHCARE PROVID	Y) DIRECTLY AND/OR THE ZATIONS deliver or otherwise provide	ROUGH GROUP
EALTHCARE PROVID	-	Γaxotere (Docetaxel) to, any
uring the time period of tw	ntified by the Plaintiff in Section renty-four (24) months preceding intiff's last administration of Tax	ant to a Group Purchasing ns V.13 and V.14 of the PFS, Plaintiff's first administration
Yes No_		
nipments of Taxotere (Doc EALTHCARE PROVIDE the PFS, for the time period dministration of Taxotere Docetaxel). Please includ	cetaxel) sold, distributed or other ERS, as identified by the Plaintiff spanning from twenty-four (24) (Docetaxel) through Plaintiff's let the name of each HEALTHCA	erwise provided to each of the f in Sections V.13 and V.14 of months prior to Plaintiff's first ast administration of Taxotere ARE PROVIDER, the date of
of Healthcare Provider	Date of Shipment	Amount of Taxotere Distributed
	Yes No YOUR answer is "Yes" hipments of Taxotere (Do EALTHCARE PROVIDI he PFS, for the time period diministration of Taxotere Docetaxel). Please includ hipment/distribution of Ta distributed on said date.	Yes No YOUR answer is "Yes" to Question A. above, please proping properties of Taxotere (Docetaxel) sold, distributed or other EALTHCARE PROVIDERS, as identified by the Plaintiffied PFS, for the time period spanning from twenty-four (24) and diministration of Taxotere (Docetaxel) through Plaintiff's Laboretaxel). Please include the name of each HEALTHCA impment/distribution of Taxotere (Docetaxel), and the amagnitude on said date.

identified by Plaintiff in Section Sections V.13 and V.14 of the PFS in effect during the time period spanning from twenty-four (24) months prior to Plaintiff's first administration of Taxotere (Docetaxel) through Plaintiff's last administration of Taxotere (Docetaxel).

D. Please provide all DOCUMENTS, including product labels, patient information packets, order forms, purchase orders, billing records, invoices, and other DOCUMENTS related to the shipments of Taxotere (Docetaxel) shipped to the HEALTHCARE PROVIDERS identified by Plaintiff in Sections V.13 and V.14 of the PFS for the time period spanning from twenty-four (24) months prior to Plaintiff's first administration of Taxotere (Docetaxel) through to Plaintiff's last administration of Taxotere (Docetaxel), and associate each label with the code numbers to which they are applicable. With regard to product labels, identification of the labels that applied to applicable lot numbers or dates is acceptable.

III. COMMUNICATIONS AND CONTACTS WITH PLAINTIFF'S HEALTHCARE PROVIDERS

- A. For each HEALTHCARE PROVIDER identified in Sections V.13 and V.14 of the PFS:
 - 1. Identify by name all of Defendants' SALES REPRESENTATIVES, MARKETING ORGANIZATIONS REPRESENTATIVES, MEDICAL SCIENCE LIAISONS, and/or any other detail persons ("Representative") who came in contact with any of Plaintiff's HEALTHCARE PROVIDER(S) in connection with Taxotere (Docetaxel) during the timeframe for which such records are available, namely 1996 to present.

Name of Representative	Title

2. Identify the time period, and specifically the dates, during which the Representative had any such contact with the HEALTHCARE PROVIDER.

Name of Representative	Healthcare Provider	Dates of Contact

3. If the Representative is no longer an employee, Defendants will provide the dates of employment for the employee and will also provide the last known address, telephone number, and email address for the Representative.

Name of	Dates of	Last Known	Telephone	Email Address
Representative	Employment	Address	Number	

4. For each Representative, provide the names of the Representative's Supervising/District SALES MANAGER. If the Representative's Supervising District SALES MANAGER is no longer an employee, Defendants will provide the dates of employment for the employee and will also provide the last known address, telephone number, and email address for the former employee.

Supervising/Dis trict SALES MANAGER	Current or Former Employee	Dates of Employment	Last Known Address	Telephone Number	Email Address

- B. For each Defendants' Sale Representatives, MARKETING ORGANIZATION REPRESENTATIVES, MEDICAL SCIENCE LIAISONS, and/or any other detail persons ("Representative"), previously identified in Section III.A of this DFS please produce the following:
 - 1. His/her complete CALL NOTES for each such contact that relates to (a) Taxotere (Docetaxel); and/or (b) hair loss; and/or (c) permanent hair loss and/or alopecia.
 - 2. Produce all emails or other written correspondence with the HEALTHCARE PROVIDER(S) that relates to (a) Taxotere (Docetaxel); and/or (b) hair loss; and/or (c) permanent hair loss and/or alopecia.
 - 3. Produce any and all TARGETING INFORMATION related to the HEALTHCARE PROVIDER(S) identified by Plaintiff in Sections V.13 and V.14 of the PFS.
- C. For the HEALTHCARE PROVIDERS identified by Plaintiff in Sections V.13 and V.14 of the PFS, please provide the following information related to SAMPLES of Taxotere (Docetaxel):
 - 1. The date(s) on which such SAMPLES of Taxotere (Docetaxel) were provided;
 - 2. The date(s) on which the Taxotere (Docetaxel) was provided through a PATIENT ASSISTANCE PROGRAM;
 - 3. The amount, dosage, and lot numbers of such SAMPLES and/or Taxotere (Docetaxel) provided through a PATIENT ASSISTANCE PROGRAM;
 - 4. The name(s) of the DEFENDANT representative(s) and/or department who provided such SAMPLES Taxotere (Docetaxel);
 - 5. The name(s) of the DEFENDANT representative(s) and/or department who provided Taxotere (Docetaxel) through a PATIENT ASSISTANCE PROGRAM.

HEALTHCARE	Date(s)	Amount and	Lot Number	Representative
PROVIDER	Shipped	Dosage		Who Provided
	and/or			
	Provided			

IV. CONSULTING WITH PLAINTIFF'S HEALTHCARE PROVIDER

For each HEALTHCARE PROVIDER identified in Plaintiff's PFS, please answer the following:

- A. If the HEALTHCARE PROVIDER has been consulted, retained, or compensated by Defendants as a "KEY OPINION LEADER," "THOUGHT LEADER," member of a "speaker's bureau," "clinical investigator," "consultant," advisory board member or in a similar capacity or otherwise has or had a financial relationship with or has been provided REMUNERATION by DEFENDANTS, please state the following for each:
 - 1. Identify the HEALTHCARE PROVIDER.
 - 2. Identify the date(s) that the HEALTHCARE PROVIDER was consulted, retained, or compensated.
 - 3. State the nature of the affiliation.
 - 4. State the type amount of REMUNERATION provided to the HEALTHCARE PROVIDER.

HEALTHCARE PROVIDER	Date(s) Consulted, Retained, or Compensated	Nature of Affiliation	REMUNERATION

5. Please identify and produce any and all consulting agreements/contracts and/or retainer agreements/contracts entered into by DEFENDANTS with the HEALTHCARE PROVIDERS identified in Sections V.13 and V.14 of the PFS.

V. PLAINTIFF'S HEALTHCARE PROVIDER'S PRACTICES

A.	treating practices		er-level data designed to track prescribing n Plaintiff's HEALTHCARE PROVIDE PFS.	•
B.		` ′	dentified in Sections V.13 and V.14 of the F y DEFENDANTS related to the treatment	
	Yes No)		
	If yes, provid	de the final Investigator	Protocol related to any such trial(s).	
		HEALTHCARE PROV y pertain to Taxotere (D	/IDER ever report any adverse events Docetaxel)?	to
	Yes	No		
	If yes, provide all D	OCUMENTS related to	the adverse event report/MedWatch form.	
		CERTIFIC	<u>ATION</u>	
DEFE were DEFE subjectrue ar to the	ion. I am author NDANTS] to execute prepared with the NDANTS, upon who at to 28 U.S.C. § 174 and correct to the best of the section.	orized bye this certification on each assistance of a number advice and information of that all of the information of my knowledge and the CUMENTS are in my presented.	, one of the DEFENDANTS in the corporation's behalf. The foregoing answers are individual, including counsel in I relied. I declare under penalty of perjuation provided in this Defendant Fact Shee at I have supplied all requested DOCUMEN possession, custody and control (including	ther vers for ury et is
Signat	ture	Print Name	Date	